Assembly Biosciences (ASMB) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ASMB · Stock Price

USD 30.93+2.47 (+8.68%)

Market Cap: $485.4M

Historical price data

Market Cap: $485.4MFounded: 2005HQ: South San Francisco, United States

Sector Ranking#211 in Small Molecule Drugs

Overview

Assembly Biosciences is a focused antiviral specialist with a mission to develop innovative therapeutics for serious viral diseases. Its strategy is validated by a major partnership with Gilead Sciences, which licensed its lead herpesvirus programs, and a clinical pipeline featuring promising candidates for HSV-2, HDV, and HBV. The company applies a targeted platform approach to discover small molecules with novel mechanisms of action, aiming to address the limitations of current standards of care.

Infectious DiseaseVirology

Technology Platform

A virology-focused platform for discovering small-molecule antivirals with novel mechanisms of action, including Helicase-Primase Inhibitors (HPIs), Core Protein Allosteric Modulators (CpAMs), and viral entry inhibitors.

Funding History

3

Total raised:$160.1M

PIPE$50MUndisclosedJul 15, 2020

IPO$85.1MUndisclosedOct 8, 2015

Series A$25MVersant VenturesMay 15, 2014

Opportunities

The Gilead partnership validates the platform and funds lead programs.

Large, underserved markets in HSV, HDV, and HBV present multi-billion dollar opportunities for novel, convenient therapies.

The company's next-generation mechanisms could become backbone agents in future combination regimens for HBV cure.

Risk Factors

High clinical-stage risk of failure; intense competition in hepatitis from large pharma; dependency on partner Gilead for lead program success; and potential future dilution to fund internal pipeline development.

Competitive Landscape

Faces competition from generic nucleoside analogs in HSV, and from large pharma and biotech in HBV/HDV. Differentiation is based on novel mechanisms (HPIs, next-gen CpAMs) and long-acting oral dosing. The Gilead partnership provides a significant commercial advantage for the herpes portfolio.